Tandem Diabetes (TNDM) Tops Q2 EPS by 14c

August 4, 2021 5:05 PM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Tandem Diabetes (NASDAQ: TNDM) reported Q2 EPS of $0.06, $0.14 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $172.1 million versus the consensus estimate of $143.63 million.


Tandem Diabetes sees FY2021 revenue of $670-685 million, versus the consensus of $637 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities